Medtronic announces new high-tech facility in Galway

New facility to manufacture drug-coated balloons technology

Global medical technology company Medtronic’s has announced it will construct a new manufacturing facility in Galway, that will manufacture the IN.PACT Admiral drug-coated balloon for the treatment of peripheral artery disease.

The decision to locate the new manufacturing facility in Galway is based on the existing high-tech capability and expertise at the site in drug-device combination products for Medtronic’s coronary business. Professionals from other parts of the Medtronic organization, approximately 100, who specialize in the areas of quality and manufacturing engineering, supply chain and production management, will be stationed in the new facility.

The facility will have 20,000 square feet of space with 8,000 square feet dedicated to manufacturing and will cost approximately €13 million. It has been specifically designed to meet the needs of the manufacturing process associated with the IN.PACT Admiral drug-coated balloon (DCB ), which is used for the interventional treatment of peripheral artery disease (PAD ) in the upper leg. This is a serious and common cardiovascular condition that affects more than 202 million people worldwide.

The announcement was made in Galway with a site-visit from Minister for Jobs Richard Bruton, and Michael Lohan, manager of Medical Technologies Division, IDA Ireland.

Tony Semedo, senior vice president and president of the Aortic & Peripheral Vascular business at Medtronic, stated that the investment showed Ireland’s importance to Medtronic’s overall growth strategy.

“Since launching the IN.PACT Admiral DCB in the US market, it has quickly become the fastest adopted DCB technology. In fact, our global market leadership in DCB is driving the need to open the new facility here in Galway to provide more patients access to this highly efficacious and safe treatment option for peripheral arterial disease," he said.

"Our Galway operations and staff have very specific expertise in this area, which is the platform for this announcement. Once fully operational, this facility will be the only DCB manufacturing area of its kind in Medtronic worldwide. Our organization is on an expansionary path, with a notable amount of this growth to be fuelled by products coming out of Ireland.”


Page generated in 0.2170 seconds.